Literature DB >> 15793151

Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.

Emilia Cantón1, Javier Pemán, Miguel Gobernado, Elena Alvarez, Fernando Baquero, Ramón Cisterna, Joaquina Gil, Estrella Martín-Mazuelos, Carmen Rubio, Aurora Sánchez-Sousa, Carmen Serrano.   

Abstract

The ability of Sensititre YeastOne to discriminate isolates with reduced caspofungin susceptibility was determined against 36 Candida spp. (6 with a known FKS1 mutation). Results were compared with those of M27-A2. The MIC endpoint was 100% growth inhibition. Overall agreement (+/-2 log2) was 87.16%. Sensititre YeastOne detected strains with reduced caspofungin susceptibility.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15793151      PMCID： PMC1068645          DOI： 10.1128/AAC.49.4.1604-1607.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; N Holliday; S B Killian
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Adding 2% glucose to culture media does not influence the activity of caspofungin against Candida species.

Authors:  M Laverdiere; C Restieri; F Habel
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

3.  Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods.

Authors:  E Cantón; J Pemán; A Carrillo-Muñoz; A Orero; P Ubeda; A Viudes; M Gobernado
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

4.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

Authors:  M A Pfaller; D J Diekema; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

6.  Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

7.  Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species.

Authors:  Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Bianca A Bouman; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

8.  Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.

Authors:  Estrella Martín-Mazuelos; Javier Pemán; Anastasio Valverde; Mónica Chaves; M Carmen Serrano; Emilia Cantón
Journal:  J Antimicrob Chemother       Date:  2003-08-13       Impact factor: 5.790

Review 9.  Caspofungin: the first in a new class of antifungal agents.

Authors:  Nicholas A Kartsonis; Jennifer Nielsen; Cameron M Douglas
Journal:  Drug Resist Updat       Date:  2003-08       Impact factor: 18.500

10.  Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus.

Authors:  C Bartizal; F C Odds
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
View more
  9 in total

1.  Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia.

Authors:  Emilia Cantón; Javier Pemán; Guillermo Quindós; Elena Eraso; Ilargi Miranda-Zapico; María Álvarez; Paloma Merino; Isolina Campos-Herrero; Francesc Marco; Elia Gomez G de la Pedrosa; Genoveva Yagüe; Remedios Guna; Carmen Rubio; Consuelo Miranda; Carmen Pazos; David Velasco
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.

Authors:  Morgan Hakki; Janet F Staab; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  The Resistant-Population Cutoff (RCOFF): a New Concept for Improved Characterization of Antimicrobial Susceptibility Patterns of Non-Wild-Type Bacterial Populations.

Authors:  Giorgia Valsesia; Michael Hombach; Florian P Maurer; Patrice Courvalin; Malgorzata Roos; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

4.  Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne method.

Authors:  Emilia Cantón; Javier Pemán; David Hervás; Carmen Iñiguez; David Navarro; Julia Echeverría; José Martínez-Alarcón; Dionisia Fontanals; Bárbara Gomila-Sard; Buenaventura Buendía; Luis Torroba; Josefina Ayats; Angel Bratos; Ferran Sánchez-Reus; Isabel Fernández-Natal
Journal:  J Clin Microbiol       Date:  2012-09-26       Impact factor: 5.948

5.  Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species.

Authors:  K Lagrou; J Verhaegen; W E Peetermans; T De Rijdt; J Maertens; E Van Wijngaerden
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-08       Impact factor: 3.267

Review 6.  Paracoccidioides brasiliensis: chemical and molecular tools for research on cell walls, antifungals, diagnosis, taxonomy.

Authors:  Gioconda San-Blas; Gustavo Niño-Vega
Journal:  Mycopathologia       Date:  2008 Apr-May       Impact factor: 2.574

7.  Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Cassaundra L Updike; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

8.  Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method.

Authors:  M A Pfaller; A Espinel-Ingroff; B Bustamante; E Canton; D J Diekema; A Fothergill; J Fuller; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; E Martin-Mazuelos; J F Meis; L Ostrosky-Zeichner; T Pelaez; G St-Germain; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

9.  RNA sequencing revealed novel actors of the acquisition of drug resistance in Candida albicans.

Authors:  Sanjiveeni Dhamgaye; Maria Bernard; Gaelle Lelandais; Odile Sismeiro; Sophie Lemoine; Jean-Yves Coppée; Stéphane Le Crom; Rajendra Prasad; Frédéric Devaux
Journal:  BMC Genomics       Date:  2012-08-16       Impact factor: 3.969
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.